Short Interest in GRI Bio, Inc. (NASDAQ:GRI) Increases By 6,284.6%

GRI Bio, Inc. (NASDAQ:GRI) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 83,000 shares, an increase of 6,284.6% from the June 15th total of 1,300 shares. Currently, 14.0% of the company’s stock are short sold. Based on an average daily volume of 122,000 shares, the days-to-cover ratio is presently 0.7 days.

GRI Bio Stock Performance

Shares of GRI opened at 1.74 on Friday. GRI Bio has a fifty-two week low of 1.46 and a fifty-two week high of 391.30. The firm’s 50-day simple moving average is 3.54 and its two-hundred day simple moving average is 11.47.

GRI Bio (NASDAQ:GRI) last posted its quarterly earnings results on Friday, May 10th. The company reported -5.98 EPS for the quarter.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.